BR112015008054A2 - formulação de fármaco de retenção gástrica e sistemas de distribuição e seu método de preparação usando carbonato de cálcio funcionalizado - Google Patents

formulação de fármaco de retenção gástrica e sistemas de distribuição e seu método de preparação usando carbonato de cálcio funcionalizado

Info

Publication number
BR112015008054A2
BR112015008054A2 BR112015008054A BR112015008054A BR112015008054A2 BR 112015008054 A2 BR112015008054 A2 BR 112015008054A2 BR 112015008054 A BR112015008054 A BR 112015008054A BR 112015008054 A BR112015008054 A BR 112015008054A BR 112015008054 A2 BR112015008054 A2 BR 112015008054A2
Authority
BR
Brazil
Prior art keywords
calcium carbonate
drug formulation
gastric retention
delivery systems
retention drug
Prior art date
Application number
BR112015008054A
Other languages
English (en)
Inventor
E Gerard Daniel
Schoelkopf Joachim
Huwyler Jörg
Puchkov Maxim
A C Gane Patrick
Alles Rainer
Anna Eberle Veronika
Original Assignee
Omya Int Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47022558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015008054(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Omya Int Ag filed Critical Omya Int Ag
Publication of BR112015008054A2 publication Critical patent/BR112015008054A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

resumo formulação de fármaco de retenção gástrica e sistemas de distribuição e seu método de preparação usando carbonato de cálcio funcionalizado uma formulação de fármaco de retenção gástrica instantaneamente flutuante compreendendo pelo menos um mineral compreendendo carbonato de cálcio natural e/ou sintético funcionalizado e pelo menos um ingrediente farmaceuticamente ativo e pelo menos um auxiliar de formulação em que o referido carbonato de cálcio natural ou sintético funcionalizado é um produto da reação de carbonato de cálcio sintético ou natural com dióxido de carbono e um ou mais ácidos, em que o dióxido de carbono é formado in situ pelo tratamento com ácido e/ou é fornecido a partir de uma fonte externa.
BR112015008054A 2012-10-12 2013-10-10 formulação de fármaco de retenção gástrica e sistemas de distribuição e seu método de preparação usando carbonato de cálcio funcionalizado BR112015008054A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12188419.1A EP2719376B1 (en) 2012-10-12 2012-10-12 Gastroretentive drug formulation and delivery systems and their method of preparation using functionalized calcium carbonate
US201261713691P 2012-10-15 2012-10-15
PCT/EP2013/071140 WO2014057026A1 (en) 2012-10-12 2013-10-10 Gastroretentive drug formulation and delivery systems and their method of preparation using functionalized calcium carbonate

Publications (1)

Publication Number Publication Date
BR112015008054A2 true BR112015008054A2 (pt) 2017-07-04

Family

ID=47022558

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015008054A BR112015008054A2 (pt) 2012-10-12 2013-10-10 formulação de fármaco de retenção gástrica e sistemas de distribuição e seu método de preparação usando carbonato de cálcio funcionalizado

Country Status (27)

Country Link
US (2) US9993428B2 (pt)
EP (2) EP2719376B1 (pt)
JP (1) JP6189445B2 (pt)
KR (2) KR20150044030A (pt)
CN (1) CN104736145B (pt)
AR (1) AR092956A1 (pt)
AU (1) AU2013328718B2 (pt)
BR (1) BR112015008054A2 (pt)
CA (1) CA2885971C (pt)
CL (1) CL2015000912A1 (pt)
DK (1) DK2719376T3 (pt)
ES (1) ES2536836T3 (pt)
HR (1) HRP20150558T1 (pt)
HU (1) HUE025008T2 (pt)
IL (1) IL237829A0 (pt)
MX (1) MX365522B (pt)
MY (1) MY183859A (pt)
PL (1) PL2719376T3 (pt)
PT (1) PT2719376E (pt)
RS (1) RS54024B1 (pt)
RU (1) RU2640914C2 (pt)
SG (1) SG11201502196TA (pt)
SI (1) SI2719376T1 (pt)
SM (1) SMT201500129B (pt)
TW (1) TWI564023B (pt)
UY (1) UY35070A (pt)
WO (1) WO2014057026A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201609445UA (en) 2014-05-30 2016-12-29 Omya Int Ag Method for the production of granules comprising surface-reacted calcium carbonate
EP2957603A1 (en) 2014-06-20 2015-12-23 Omya International AG Method for the production of granules comprising surface-reacted calcium carbonate
EP2949708B1 (en) 2014-05-30 2018-04-04 Omya International AG Method for the production of granules comprising surface-reacted calcium carbonate
EP3034070A1 (en) 2014-12-18 2016-06-22 Omya International AG Method for the production of a pharmaceutical delivery system
EP3069713A1 (en) 2015-03-20 2016-09-21 Omya International AG Dispersible dosage form
EP3167879A1 (en) * 2015-11-10 2017-05-17 Evonik Technochemie GmbH Gastric retention active delivery systems
EP3176222A1 (en) 2015-12-01 2017-06-07 Omya International AG Method for the production of granules comprising surface-reacted calcium carbonate
EP3260114A1 (en) * 2016-06-21 2017-12-27 Omya International AG Method for the production of a dosage form
EP3260115A1 (en) * 2016-06-21 2017-12-27 Omya International AG Method for the production of a dosage form
EP3269361A1 (en) 2016-07-14 2018-01-17 Omya International AG Dosage form
EP3275946A1 (en) * 2016-07-25 2018-01-31 Omya International AG Post treatment of surface-reacted calcium carbonate with different functional cations
EP3275947A1 (en) 2016-07-25 2018-01-31 Omya International AG Surface-reacted calcium carbonate with functional cations
EP3275537A1 (en) * 2016-07-25 2018-01-31 Omya International AG Surface-modified calcium carbonate as carrier for transition metal-based catalysts
EP3562486B1 (en) 2016-12-31 2024-03-13 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
CN106732678B (zh) * 2017-01-20 2019-05-14 中国科学院西双版纳热带植物园 一种碳基磁性固体酸催化剂及其在生物柴油制备中的应用
CA3031412C (en) 2017-06-16 2020-08-11 Kashiv Pharma Llc Gastroretentive dosage forms for sustained drug delivery
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
CN107522216B (zh) * 2017-07-20 2019-07-23 莆田学院 一种利用咪唑-4,5-二羧酸改性壳聚糖仿生合成微球球霰石的方法
EP3609472B1 (en) 2018-06-18 2020-12-30 Kashiv Specialty Pharmaceuticals, LLC Extended release compositions comprising pyridostigmine
EP3813802A4 (en) 2018-06-27 2022-06-08 Bioxcel Therapeutics, Inc. FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEM
MX2022000709A (es) 2019-07-19 2022-05-19 Bioxcel Therapeutics Inc Regimenes de tratamiento con dexmedetomidina no sedante.
CA3175218A1 (en) 2020-04-28 2021-11-04 Laura DE MIGUEL Method for the production of free-flowing granules
TW202200206A (zh) 2020-04-28 2022-01-01 瑞士商歐米亞國際公司 包含表面反應碳酸鈣作為賦形劑之顆粒
CN111467317B (zh) * 2020-05-22 2022-03-15 福建海西新药创制有限公司 一种含有阿托伐他汀钙的药物组合物及其制备方法
EP3928859A1 (en) 2020-06-23 2021-12-29 Omya International AG Surface-reacted calcium carbonate in a process for the production of a loaded microcapsule
US20230000900A1 (en) * 2021-07-05 2023-01-05 Reflux Gourmet Llc Method for neutralizing stomach acid using alginate, polylysine, and seed preservatives
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3418999A (en) 1964-02-12 1968-12-31 Donald W. Davis Method of swallowing a pill
JPS5512411B2 (pt) 1974-03-12 1980-04-02
ZA761305B (en) * 1975-03-17 1977-02-23 Hoffmann La Roche Sustained release formulation
JPS56101694A (en) 1980-01-18 1981-08-14 Nec Corp Semiconductor circuit
US4451260A (en) 1982-03-26 1984-05-29 Minnesota Mining And Manufacturing Company Sustained release oral medicinal delivery device
JPS6143108A (ja) 1984-08-03 1986-03-01 Nippon Shinyaku Co Ltd 医薬品製剤及びその製造法
PL149493B1 (en) 1985-04-12 1990-02-28 Method of obtaining a tablet capable to buoy over surface of gastric juice
JPH0798742B2 (ja) * 1986-07-03 1995-10-25 ゼリア新薬工業株式会社 徐放性製剤組成物
GB8809421D0 (en) 1988-04-21 1988-05-25 Fordonal Sa Antacid compositions with prolonged gastric residence time
DE69428707T2 (de) 1993-08-20 2002-07-11 Nippon Shinyaku Co Ltd Im magen verbleibende zubereitung, quellender formkörper und herstellungsverfahren
FR2762213B1 (fr) * 1997-04-18 1999-05-14 Synthelabo Composition pharmaceutique a retention gastrique
US20010046473A1 (en) * 1997-04-18 2001-11-29 Jerome Besse Gastric-retained pharmaceutical composition and method for its use
FR2787802B1 (fr) 1998-12-24 2001-02-02 Pluss Stauffer Ag Nouvelle charge ou pigment ou mineral traite pour papier, notamment pigment contenant du caco3 naturel, son procede de fabrication, compositions les contenant, et leurs applications
FR2852600B1 (fr) 2003-03-18 2005-06-10 Nouveau pigment mineral contenant du carbonate de calcium, suspension aqueuse le contenant et ses usages
US20050202084A1 (en) * 2003-07-10 2005-09-15 Prasad Adusumilli Pharmaceutical compositions
FR2881957B1 (fr) * 2005-02-16 2008-08-08 Solvay Comprimes comprenant une substance biologiquement active et un excipient
PL2070991T3 (pl) 2007-12-12 2011-02-28 Omya Int Ag Sposób wytwarzania strącanego węglanu wapnia o powierzchni zmodyfikowanej chemicznie
WO2010035273A2 (en) * 2008-09-29 2010-04-01 Intec Pharma Ltd. Novel gastroretentive delivery system
EP2168572A1 (en) * 2008-09-30 2010-03-31 Omya Development Ag New controlled release active agent carrier
JP2012508773A (ja) * 2008-11-14 2012-04-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 低いｐＨでの難水溶性のイオン化活性薬剤の制御放出のための固体組成物およびその使用方法
PL2264108T3 (pl) 2009-06-15 2012-07-31 Omya Int Ag Sposób wytwarzania przereagowanego powierzchniowo węglanu wapnia, z wykorzystaniem słabego kwasu
TWI625129B (zh) 2011-11-10 2018-06-01 歐米亞國際公司 新穎的經塗布控釋活性劑載體

Also Published As

Publication number Publication date
JP2015533139A (ja) 2015-11-19
AR092956A1 (es) 2015-05-06
MY183859A (en) 2021-03-17
CA2885971C (en) 2018-01-02
KR20170103989A (ko) 2017-09-13
AU2013328718B2 (en) 2016-07-21
KR20150044030A (ko) 2015-04-23
AU2013328718A1 (en) 2015-04-09
PT2719376E (pt) 2015-07-06
RS54024B1 (en) 2015-10-30
CA2885971A1 (en) 2014-04-17
MX2015004084A (es) 2015-07-06
JP6189445B2 (ja) 2017-08-30
CN104736145B (zh) 2017-06-23
RU2015117534A (ru) 2016-11-27
US9993428B2 (en) 2018-06-12
DK2719376T3 (en) 2015-06-15
US20150231078A1 (en) 2015-08-20
US9987230B2 (en) 2018-06-05
IL237829A0 (en) 2015-05-31
EP2719376A1 (en) 2014-04-16
PL2719376T3 (pl) 2015-08-31
SMT201500129B (it) 2015-07-09
US20160256393A1 (en) 2016-09-08
TW201427689A (zh) 2014-07-16
CL2015000912A1 (es) 2016-05-13
CN104736145A (zh) 2015-06-24
UY35070A (es) 2014-05-30
WO2014057026A1 (en) 2014-04-17
TWI564023B (zh) 2017-01-01
SG11201502196TA (en) 2015-04-29
ES2536836T3 (es) 2015-05-29
HRP20150558T1 (hr) 2015-07-03
RU2640914C2 (ru) 2018-01-12
SI2719376T1 (sl) 2015-06-30
HUE025008T2 (en) 2016-04-28
MX365522B (es) 2019-06-06
EP2719376B1 (en) 2015-03-04
EP2906200A1 (en) 2015-08-19

Similar Documents

Publication Publication Date Title
BR112015008054A2 (pt) formulação de fármaco de retenção gástrica e sistemas de distribuição e seu método de preparação usando carbonato de cálcio funcionalizado
BR112015008139A2 (pt) formulação de forma de dosagem sólida de desintegração rápida compreendendo carbonato de cálcio funcionalizado e método de fabricação dos mesmos
BR112017010662A2 (pt) sistema de travamento mecânico para painéis de piso
CO2017005500A2 (es) Método para la producción de un sistema de administración farmacéutica
BR112017005780A2 (pt) ?uso de um carbonato de cálcio reagido na superfície como agente antiaglomerante, métodos para controlar, reduzir ou evitar aglomeração de uma composição particulada e para produzir uma composição, e, composição?
BR112013004440A2 (pt) método para administração parenteral de uma composição, composição farmacêutica para administração parenteral, kit e sistema farmacêutico para administração parenteral
BR112015023658A2 (pt) formulação de vitamina d de liberação modificada, estabilizada e método de administração desta
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
BR112017022846A2 (pt) combinação de dose fixa inviolável que proporciona rápida liberação de dois fármacos de partículas diferentes
BR112014032627A8 (pt) Pró-fármacos de rebamipida, método para produzir o mesmo, e uso do mesmo
MX2019005160A (es) Formulacion farmaceutica.
AR076576A1 (es) Procedimiento para estabilizar un suplemento dietetico para facilitar la salud de las articulaciones en seres humanos
BR112017015782A2 (pt) combinação de duas ou mais enzimas de lípase, preparação farmacêutica, uso de uma combinação de duas ou mais enzimas de lípase, método para a produção de uma combinação de duas ou mais enzimas de lípases e duas ou mais moléculas de ácido nucléico
BR112017022856A2 (pt) combinação de dose fixa inviolável que proporciona rápida liberação de duas drogas a partir de partículas
BR112016017496A2 (pt) Composição para acelerar a penetração através da pele, preparação para administração transdérmica e preparação de emplastro de pele
BR112015015938A2 (pt) uso de cloridrato de fenilefrina e paracetamol, medicamento, método de tratamento de congestão das mucosas do trato respiratório superior em um humano adulto
PE20141022A1 (es) Composiciones y procedimientos para la administracion de nutrientes
BR112017022335A2 (pt) combinação de dose fixa inviolável que fornece rápida liberação de dois fármacos a partir de partículas e matriz
CO2020007892A2 (es) Uso de carbonato de calcio funcionalizado como ingrediente activo
PH12015501211A1 (en) Use of pidotimod to treat atopic dermatitis
WO2015074667A3 (en) Composition for dermatitis
BR112017022855A2 (pt) combinação de dose fixa inviolável que provê liberação rápida de dois fármacos a partir de partículas e um pó
WO2013127539A3 (de) Pharmazeutische formulierung enthaltend flupirtin
AR104146A1 (es) Composición farmacéutica o suplemento dietético para el tratamiento de neuropatías y/o dolor neuropático
UA111785C2 (uk) Композиція для лікування бородавок та спосіб лікування бородавок

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]